Neuropathic Pain in Patients With Cancer
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer
연구 개요
상세 설명
Neuropathic pain is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to harmless as well as harmful stimuli. This type of pain is extremely difficult to manage, fails to respond to standard analgesic medications or interventions, and often gets worse instead of better over time. Current approved therapeutic agents often have intolerable side effects and limited efficacy. Thus, there is an urgent need to develop safe and effective drugs to treat neuropathic pain.
Study DTCL100 will be conducted at multiple centers and will enroll patients that have advanced cancer AND neuropathic pain that has not responded well to previous treatment. Eighteen patients will be randomly assigned to receive up to 8 doses of active drug (KRN5500) or placebo. A maximum of 8 doses will be administered weekly over a 10 week period. Patients are encouraged to complete at least 4 treatment visits before a decision is made to complete the full 10 weeks of treatment and the 1 month followup period.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90025
- Cancer Institute Medical Group
-
Los Angeles, California, 미국, 90027
- Ghassan Al-Jazayrly, M.D., Inc.
-
Orange, California, 미국, 92868
- University of California / Irvine Chao Family Comprehensive Cancer Center
-
-
Florida
-
Jupiter, Florida, 미국, 33477
- Keog Pharma, Inc.
-
-
Louisiana
-
Covington, Louisiana, 미국, 70433
- Hematology And Oncology Specialists, Llc
-
-
Maryland
-
Baltimore, Maryland, 미국, 21229
- St. Agnes Healthcare, Inc
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
New Jersey
-
East Orange, New Jersey, 미국, 07018
- East Orange VA Medical Center
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, 미국, 27103
- Carolina Pain Institute, PA
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00921
- Dr. Rivera-Colon
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 years or older
- Diagnosis of advanced or recurrent cancer
- No options for curative chemotherapy, but palliative chemotherapy allowed under certain conditions
- Refractory neuropathic pain rated 4 or greater on 0-10 scale and failure to respond to 2 commonly used treatments
- If taking opioids for pain, stable regimen over past week before enrolling
- Karnofsky performance status of 40 or more
- Females must be sterile or post-menopausal
Exclusion Criteria:
- Radiation to site of neuropathic pain for past 4 weeks
- Major surgery within past 2 weeks
- Liver function and other key labs outside normal parameters
- ECG showing significant abnormality
- Myocardial Infarction (heart attack) within past 6 months
- History of interstitial lung disease
- History of severe allergic reaction to drugs containing polysorbate 80
- Other investigational drug within 2 weeks or 5 half-lives (whichever is longer
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: KRN5500
KRN5500 escalating dose of .6,
1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
|
Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo .
The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
|
|
위약 비교기: Normal Saline
Placebo consists of IV infusion of normal saline
|
Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo .
The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Normal Saline given as dose escalation for placebo
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Average pain intensity over the previous 24 hours as measured by a numeric rating scale (NRS) ranging from 0 to 10 where 0 represents "no pain" and 10 represents the "worst possible pain."
기간: Weekly for 10 weeks plus 30 day followup
|
Weekly for 10 weeks plus 30 day followup
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Physical Examination, Vital signs and body weight, Electrocardiogram, Laboratory parameters, Adverse events, Clinical Opiate Withdrawal Scale, rescue medication, Proportion of patients who achieved a 33% reduction in pain intensity
기간: Weekly for 10 weeks plus 30 day followup
|
Weekly for 10 weeks plus 30 day followup
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Richard Penson, MD, MRCP, Massachusetts General Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
KRN5500에 대한 임상 시험
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)완전한